These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 11535548)

  • 1. Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind, placebo-controlled, randomized clinical trial in postmenopausal patients.
    Dowsett M; Bundred NJ; Decensi A; Sainsbury RC; Lu Y; Hills MJ; Cohen FJ; Veronesi P; O'Brien ME; Scott T; Muchmore DB
    Cancer Epidemiol Biomarkers Prev; 2001 Sep; 10(9):961-6. PubMed ID: 11535548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.
    Martino S; Cauley JA; Barrett-Connor E; Powles TJ; Mershon J; Disch D; Secrest RJ; Cummings SR;
    J Natl Cancer Inst; 2004 Dec; 96(23):1751-61. PubMed ID: 15572757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiproliferative effects of idoxifene in a placebo-controlled trial in primary human breast cancer.
    Dowsett M; Dixon JM; Horgan K; Salter J; Hills M; Harvey E
    Clin Cancer Res; 2000 Jun; 6(6):2260-7. PubMed ID: 10873076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
    Baselga J; Semiglazov V; van Dam P; Manikhas A; Bellet M; Mayordomo J; Campone M; Kubista E; Greil R; Bianchi G; Steinseifer J; Molloy B; Tokaji E; Gardner H; Phillips P; Stumm M; Lane HA; Dixon JM; Jonat W; Rugo HS
    J Clin Oncol; 2009 Jun; 27(16):2630-7. PubMed ID: 19380449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk.
    Lippman ME; Cummings SR; Disch DP; Mershon JL; Dowsett SA; Cauley JA; Martino S
    Clin Cancer Res; 2006 Sep; 12(17):5242-7. PubMed ID: 16951244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of tibolone on breast cancer cell proliferation in postmenopausal ER+ patients: results from STEM trial.
    Kubista E; Planellas Gomez JV; Dowsett M; Foidart JM; Pohlodek K; Serreyn R; Nechushkin M; Manikhas AG; Semiglazov VF; Hageluken CC; Singer CF
    Clin Cancer Res; 2007 Jul; 13(14):4185-90. PubMed ID: 17634547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
    Burshell AL; Song J; Dowsett SA; Mershon JL; Delmas PD; Secrest RJ; Cauley JA
    Curr Med Res Opin; 2008 Mar; 24(3):807-13. PubMed ID: 18254988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.
    McClung MR; Siris E; Cummings S; Bolognese M; Ettinger M; Moffett A; Emkey R; Day W; Somayaji V; Lee A
    Menopause; 2006; 13(3):377-86. PubMed ID: 16735934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer.
    Robertson JF; Nicholson RI; Bundred NJ; Anderson E; Rayter Z; Dowsett M; Fox JN; Gee JM; Webster A; Wakeling AE; Morris C; Dixon M
    Cancer Res; 2001 Sep; 61(18):6739-46. PubMed ID: 11559545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety assessment of raloxifene over eight years in a clinical trial setting.
    Martino S; Disch D; Dowsett SA; Keech CA; Mershon JL
    Curr Med Res Opin; 2005 Sep; 21(9):1441-52. PubMed ID: 16197663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of raloxifene on sex steroid hormones and C-telopeptide in postmenopausal women with primary breast cancer.
    Johansson H; Bonanni B; Mariette F; Cazzaniga M; Baglietto L; Guerrieri-Gonzaga A; Sandri MT; Luini A; Pelosi G; Decensi A
    Breast Cancer Res Treat; 2006 Jul; 98(2):167-72. PubMed ID: 16538534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women.
    Lee WL; Chao HT; Cheng MH; Wang PH
    Maturitas; 2008 Jun; 60(2):92-107. PubMed ID: 18534794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women.
    Barrett-Connor E; Mosca L; Collins P; Geiger MJ; Grady D; Kornitzer M; McNabb MA; Wenger NK;
    N Engl J Med; 2006 Jul; 355(2):125-37. PubMed ID: 16837676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of hot flushes in postmenopausal women who receive raloxifene therapy.
    Aldrighi JM; Quail DC; Levy-Frebault J; Aguas F; Kosian K; Garrido L; Bosio-Le Goux B; Saráchaga M; Graebe A; Niño AJ; Nickelsen T
    Am J Obstet Gynecol; 2004 Dec; 191(6):1979-88. PubMed ID: 15592280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of selective estrogen receptor modulators on breast cancer: from tamoxifen to raloxifene.
    Lee WL; Cheng MH; Chao HT; Wang PH
    Taiwan J Obstet Gynecol; 2008 Mar; 47(1):24-31. PubMed ID: 18400579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of raloxifene on telomerase expression in breast carcinoma samples from postmenopausal women.
    dos Santos LG; da Silva BB
    Eur J Obstet Gynecol Reprod Biol; 2011 Nov; 159(1):165-7. PubMed ID: 21741149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial.
    Usall J; Huerta-Ramos E; Iniesta R; Cobo J; Araya S; Roca M; Serrano-Blanco A; Teba F; Ochoa S
    J Clin Psychiatry; 2011 Nov; 72(11):1552-7. PubMed ID: 21903021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study.
    Miller PD; Chines AA; Christiansen C; Hoeck HC; Kendler DL; Lewiecki EM; Woodson G; Levine AB; Constantine G; Delmas PD
    J Bone Miner Res; 2008 Apr; 23(4):525-35. PubMed ID: 18072873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Piloting the effective therapeutic dose of adjunctive selective estrogen receptor modulator treatment in postmenopausal women with schizophrenia.
    Kulkarni J; Gurvich C; Lee SJ; Gilbert H; Gavrilidis E; de Castella A; Berk M; Dodd S; Fitzgerald PB; Davis SR
    Psychoneuroendocrinology; 2010 Sep; 35(8):1142-7. PubMed ID: 20171784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transition to raloxifene with and without low-dose estrogen therapy in postmenopausal women: effects on serum lipids and fibrinogen - a pilot study.
    O'Neill SM; Eden J; Baber R; Ekangaki A; Stocks JM; Wolthers T; Davis SR
    Climacteric; 2003 Dec; 6(4):347-53. PubMed ID: 15006256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.